Welcome to our dedicated page for Butterfly Network news (Ticker: BFLY), a resource for investors and traders seeking the latest updates and insights on Butterfly Network stock.
Butterfly Network, Inc. develops semiconductor-based ultrasound devices, programmable cloud software and AI for medical imaging and sensing. Its Ultrasound-on-Chip technology underpins handheld whole-body ultrasound systems such as Butterfly iQ, iQ+ and iQ3, along with enterprise workflow software including Compass AI and developer tools such as Butterfly Garden.
Company news commonly covers financial results, point-of-care ultrasound adoption, FDA-cleared AI tools such as its Gestational Age Tool, U.S. and international sales channels, and platform initiatives. Updates also address Butterfly Embedded, the company’s licensing and co-development effort for applying its ultrasound chip and software platform in partner-built products, as well as board and leadership changes tied to medtech, clinical strategy and commercialization.
Butterfly Network (NYSE: BFLY) announced GovRAMP and TX-RAMP authorizations for its Butterfly iQ+/iQ3 probes and Compass AI™ cloud workflow, enabling sales to all state and local government agencies including Texas.
The solution completed a third-party assessment by A-LIGN and a GovRAMP PMO quality review; Butterfly is pursuing FedRAMP in 2026 and additional certifications.
Butterfly Network (NYSE: BFLY) will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 at 8:00 AM ET.
Joseph DeVivo, President and CEO, and John Doherty, EVP and CFO, will host a pre-market conference call and webcast to discuss financial performance and operational progress. The live webcast will be archived and a telephone replay is available through March 5, 2026.
Butterfly Network (NYSE: BFLY) said it expects fourth-quarter 2025 revenue growth of at least 17% year-over-year. The company described momentum in its handheld ultrasound business and highlighted plans to expand co-development and chip licensing opportunities, calling 2026 a potential inflection year. Butterfly will present a business update at the 44th J.P. Morgan Healthcare Conference on January 15, 2026 at 9:00 AM PST. The company said audited fourth-quarter and full-year 2025 results and 2026 guidance are expected in late February 2026. A webcast of the JP Morgan presentation will be available for replay through February 15, 2026.
Butterfly Network (NYSE: BFLY) announced a planned Beam Steering API release expected in first half of 2026 to allow third-party developers in Butterfly Garden and Ultrasound-on-Chip co-development programs to access its electronically steered 3D imaging capabilities.
The API exposes software-defined beam steering features (including off-axis beam tilt up to 20 degrees) previously reserved for Butterfly apps and is built on a semiconductor CMUT array with approximately 9,000 elements. The SDK is expected to support a subset of presets across abdominal, cardiac, obstetric, musculoskeletal, vascular, and lung imaging. Availability and technical scope depend on ongoing development, regulatory considerations, and partner agreements.
Butterfly Network (NYSE: BFLY) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2026 at 9:00 AM PST. Company executives Joseph DeVivo, John Doherty, and Megan Carlson will host investor meetings and deliver the presentation.
A webcast will be posted in the company's Events & Presentations investor section and will be available for replay through February 15, 2026. Investors may schedule one-on-one meetings via company contacts or through J.P. Morgan representatives.
Butterfly Network (NYSE: BFLY) will participate at the 8th Annual Evercore Healthcare Conference in Coral Gables, FL on Tuesday, December 2, 2025. Joseph DeVivo, President, CEO & Chairman, and Megan Carlson, Senior VP & Interim CFO, will take part in a fireside chat at 1:20 PM ET and will host one-on-one investor meetings.
A live webcast of the fireside chat will be available in the Events & Presentations section of the Butterfly investor website and will be available for replay after the event. One-on-one meetings can be scheduled through Evercore representatives.
Butterfly Network (NYSE:BFLY) launched Compass AI on November 17, 2025 — an AI-powered enterprise platform to manage scalable, revenue-ready point-of-care ultrasound (POCUS) programs.
Key claims: documentation compliance up to 94% (vs ~15% for traditional workflows), up to 5x more revenue from the same clinical volume, and charting time cut by up to 25%. Features include ambient Documentation Agent, AI QA Agent, Program Dashboard, EHR/PACS/SSO integration and Fleet Visibility. Compass AI is available immediately for demonstrations.
Butterfly Network (NYSE: BFLY) reported Q3 2025 results with $21.5M revenue (5% YoY) and reaffirmed full-year revenue guidance of $91M–$95M. The company reduced quarterly cash burn to a record low of $3.9M and held $144.2M cash at quarter-end. GAAP gross margin swung to a (17.5%) loss due to a $17.4M inventory write-down while adjusted gross margin rose to 63.9%. Net loss widened to $34.0M and adjusted EBITDA loss improved slightly to $8.1M. Operational milestones included ISO 27001, a JAMA clinical validation, FDA-submitted gestational-age AI, third-party app launch in Butterfly Garden, and P5.1 chip completion.
Butterfly Network (NYSE: BFLY) said its CEO and interim CFO will participate at the UBS Global Healthcare Conference in Palm Beach, FL on Tuesday, November 11, 2025 at 5:00 pm ET.
Joseph DeVivo, President, CEO & Chairman and Megan Carlson, SVP & Interim CFO will take part in a fireside chat and host one-on-one investor meetings. A live webcast will be available in the Events & Presentations section of the Butterfly investor website and will be available for replay after the event. One-on-one meetings are scheduled through UBS representatives.
Butterfly Network (NYSE:BFLY) announced it achieved multiple information-security accreditations on October 27, 2025, reinforcing its global data-protection posture.
The company obtained ISO 27001, SOC-2 Type 2, C5 Germany, and the NHS DSPT certifications, and was assessed by third-party auditor A-LIGN. Management said these certifications support enterprise-grade, secure medical imaging for hospitals and health systems across the US, UK, EU, and international markets.
The release also reiterates prior milestones: a 2024 GovRAMP Snapshot (first in medical imaging) and ongoing pursuits of full GovRAMP authorization, TX-RAMP, FedRAMP, and HITRUST CSF r2.